Revenue
2009
2010
2011
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Heron Therapeutics, Inc. (HRTX)
Price$0.3431Cached quote
Net income
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $154.9M | $144.3M | $127.0M | $107.7M | $86.3M | $88.6M | $146.0M | $77.5M | $30.8M | $1.3M | — | — | — | — | $646,000 | $1.3M | $1.3M |
| Gross profit | $113.6M | $105.6M | $61.9M | $52.8M | $40.3M | $52.4M | $84.3M | $50.0M | $26.2M | $1.2M | — | — | — | — | — | — | — |
| Gross margin | 73.31% | 73.21% | 48.75% | 49.04% | 46.70% | 59.17% | 57.79% | 64.49% | 85.09% | 97.26% | — | — | — | — | — | — | — |
| Research & development | $12.4M | $16.7M | $39.1M | $82.7M | $130.8M | $174.5M | $167.4M | $140.0M | $138.6M | $103.1M | $61.2M | $54.8M | $32.5M | $15.2M | $8.2M | $7.3M | $7.8M |
| Operating expenses | $116.1M | $117.2M | $172.6M | $282.3M | $304.2M | $316.8M | $356.7M | $261.4M | $225.3M | $172.2M | $96.9M | $74.6M | $54.5M | $23.8M | $11.7M | $11.2M | $11.5M |
| Operating income | −$2.5M | −$11.5M | −$110.6M | −$174.7M | −$217.8M | −$228.2M | −$210.7M | −$183.9M | −$194.6M | −$170.9M | −$96.9M | −$74.6M | −$54.5M | −$23.8M | −$11.1M | −$9.9M | −$10.2M |
| Operating margin | −1.64% | −7.99% | −87.07% | −162.21% | −252.27% | −257.41% | −144.34% | −237.42% | −632.36% | −13,363.17% | — | — | — | — | −1,712.38% | −763.57% | −812.21% |
| EBITDA | −$224,000 | −$9.0M | −$107.7M | −$171.8M | −$214.8M | −$225.3M | −$208.7M | −$182.4M | −$193.0M | −$169.8M | −$96.2M | −$74.0M | −$54.1M | −$23.6M | −$10.9M | −$9.7M | −$9.9M |
| EBITDA margin | −0.14% | −6.26% | −84.79% | −159.53% | −248.77% | −254.20% | −142.94% | −235.46% | −627.38% | −13,277.25% | — | — | — | — | −1,684.67% | −746.12% | −783.98% |
| Net income | −$20.2M | −$13.6M | −$110.6M | −$182.0M | −$220.7M | −$227.3M | −$204.7M | −$178.8M | −$197.5M | −$173.1M | −$97.6M | −$76.4M | −$55.3M | −$23.3M | −$11.8M | −$7.3M | −$10.0M |
| Net profit margin | −13.04% | −9.41% | −87.02% | −169.05% | −255.58% | −256.41% | −140.27% | −230.84% | −641.87% | −13,537.37% | — | — | — | — | −1,828.79% | −564.64% | −795.24% |
| Basic EPSper basic share | -$0.12 | -$0.09 | -$0.80 | -$1.67 | -$2.24 | -$2.50 | -$2.50 | -$2.44 | -$3.65 | -$4.56 | -$2.95 | -$2.87 | -$3.42 | -$1.91 | -$1.96 | -$3.80 | -$6.20 |
| Diluted EPSper diluted share | -$0.12 | -$0.09 | -$0.80 | -$1.67 | -$2.24 | -$2.50 | -$2.50 | -$2.44 | -$3.65 | -$4.56 | -$2.95 | -$2.87 | -$3.42 | -$1.91 | -$1.96 | -$3.80 | -$6.20 |
Owners
Reported shareholders
Reported holdings Number of shares
View holders
| Holder | Shares held |
|---|---|
Rubric Capital Management LP | 30.05M |
Clearline Capital LP | 11.38M |
BlackRock, Inc. | 10.55M |
Morgan Adam | 8.88M |
Velan Capital Investment Management LP | 8.75M |
VANGUARD CAPITAL MANAGEMENT LLC | 7.78M |
Tejara Capital Ltd | 6.51M |
TANG CAPITAL MANAGEMENT LLC | 6.25M |
GEODE CAPITAL MANAGEMENT, LLC | 4.27M |
MILLENNIUM MANAGEMENT LLC | 4.07M |
JW Asset Management, LLC | 3.75M |
STATE STREET CORP | 3.23M |
UBS Group AG | 3M |
Pale Fire Capital SE | 2.51M |
MARSHALL WACE, LLP | 2.35M |
Congress Park Capital LLC | 2.02M |
Richmond Brothers, Inc. | 1.79M |
VANGUARD PORTFOLIO MANAGEMENT LLC | 1.58M |
AQR CAPITAL MANAGEMENT LLC | 1.55M |
RENAISSANCE TECHNOLOGIES LLC | 1.51M |
Bars compare reported share counts. A matching total for this share class and reporting period is unavailable, so percentages are not shown.
Source: SEC Form 13F ↗Updated Sep 29, 2026 · Quarterly data
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Aug 8, 2025Form 4 | Morgan AdamDirector | BuyCommon Stock · indirect | 1.77M | $1.50 | $2.65M | 8.75M |
| Aug 8, 2025Form 4 | Morgan AdamDirector | BuySeries A Convertible Preferred Stock · derivative · indirect | 70.0K | $15.00 | $1.05M | 70.0K |
| Aug 8, 2025Form 4 | Rosen David Efraim +1TenPercentOwner | BuyCommon Stock, par value $0.01 per share ("Common Stock") · indirect | 2.39M | $1.50 | $3.58M | 29.10M |
| Aug 8, 2025Form 4 | Rosen David Efraim +1TenPercentOwner | BuySeries A Convertible Preferred Stock ("Preferred Shares") · derivative · indirect | — | $15.00 | — | — |
| Aug 8, 2025Form 4 | Rosen David Efraim +1TenPercentOwner | BuyConvertible Senior Unsecured Promissory Notes ("Notes") · derivative · indirect | 94.6K | $33.25M | $35.00M | 94.6K |